Playtex Adds Production Lot to its March 2014 Voluntary Recall of Certain AC/DC Power Adapters used with the Playtex® Nurser Deluxe Double Electric Breast Pump
Playtex Media Contact: Catherine McCormack, Edelman, 212-819-4816
Shelton, CT. September 9, 2014 – Energizer Personal Care – Playtex Manufacturing, Inc.
announced today that, out of an abundance of caution, it is adding an adapter production lot to its voluntary nationwide recall of certain AC/DC power adapters that are used with the Playtex® Nurser Deluxe Double Electric Breast Pump. No injuries have been reported to date.
In March 2014, Playtex announced a voluntary recall of certain AC/DC power adapters because the casing on some adapters may come loose and separate, resulting in a potential for electric shock. After further evaluation and investigation, Playtex has added one adapter production lot to the recall.
The affected adapters were manufactured from November 2012 through July 2013. The products can be identified by product serial number (P12315 -XXXX through P13205-XXXX). Alternatively, the product can be identified by adapter production code (1238 through 1324). The adapters were sold along with the Playtex Nurser Deluxe Double Electric Breast Pump. They were not sold separately.
The Playtex Nurser Deluxe Double Electric Breast Pump was sold at nationwide, specialty and online retailers. Playtex is notifying its retail partners to return any remaining products with affected AC/DC adapters.
Consumers who have purchased an affected product should contact Playtex for a replacement by calling 1-888-207-1429 from 8 a.m. to 6 p.m. ET Monday through Friday or contact us online. Consumers should immediately discontinue use of the adapter if it shows signs of separating.
This recall is specific to certain AC/DC adapters sold with the Playtex Nurser Deluxe Double Electric Breast Pump, and is being conducted in conjunction with the U.S. Food and Drug Administration (FDA).
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.